APA (7th ed.) Citation

Fatema Alrashed, Israa Abdullah, Ahmad Alfadhli, Mohammad Shehab, Mohammad Shehab, & Mohammad Shehab. (2023). Effectiveness of vedolizumab and ustekinumab as second biologic agent in achieving target outcomes in tumor necrosis factor antagonists experienced patients with inflammatory bowel disease (enroll-ex study). Frontiers Media S.A..

Chicago Style (17th ed.) Citation

Fatema Alrashed, Israa Abdullah, Ahmad Alfadhli, Mohammad Shehab, Mohammad Shehab, and Mohammad Shehab. Effectiveness of Vedolizumab and Ustekinumab as Second Biologic Agent in Achieving Target Outcomes in Tumor Necrosis Factor Antagonists Experienced Patients with Inflammatory Bowel Disease (enroll-ex Study). Frontiers Media S.A., 2023.

MLA (9th ed.) Citation

Fatema Alrashed, et al. Effectiveness of Vedolizumab and Ustekinumab as Second Biologic Agent in Achieving Target Outcomes in Tumor Necrosis Factor Antagonists Experienced Patients with Inflammatory Bowel Disease (enroll-ex Study). Frontiers Media S.A., 2023.